Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Tilapertin for schizophrenia negative symptoms
NCT01568216Phase 2Terminated
- Sponsor
- Amgen
- Start
- May 2012
- Primary completion
- Jun 2013
- Modality
- Small Molecules
- Countries
- 7
01
Overview
Phase 2, randomised, double-blind trial of tilapertin in schizophrenia (4 arms), sponsored by Amgen. Primary endpoint: Negative Symptom Assessment-16 Total Score at 12 weeks. Started May 2012; status: terminated.
02
Drugs
tilapertin
03
Conditions
schizophrenia
Beyond the preview
Go deeper on NCT01568216.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT01568216.